A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
10/2002
10/31/2002	WO2002085309A2 Composition, formulations & kits for treatment of respiratory & lung disease with anti-sense oligonucleotides & a bronchodilating agent
10/31/2002	WO2002085308A2 Antisense and anti-inflammatory based compositions to treat respiratory disorders
10/31/2002	WO2002085304A2 Proliposomal drug delivery system
10/31/2002	WO2002085303A2 Substituted tetracycline compounds for the treatment of malaria
10/31/2002	WO2002085301A2 Indole, azaindole and related heterocyclic amidopiperazine derivatives
10/31/2002	WO2002085297A2 Compositions & formulations with a non-glucocorticoid steroid &/or a ubiquinone & kit for treatment of respiratory & lung disease
10/31/2002	WO2002085296A2 Composition, formulations and kit for treatment of respiratory and lung disease with non-glucocorticoid steroids and/or ubiquinone and a bronchodilating agent
10/31/2002	WO2002085292A2 Improved method for treating aberrant fibrotic tisue manifestations with topical calcium channel blocker preparations and improved composition for such treatment and improved method for the manufacture thereof
10/31/2002	WO2002085291A2 Nociceptin analogs
10/31/2002	WO2002085268A1 Disposal system for transdermal dosage form
10/31/2002	WO2002085255A1 Improved surgical stent and method for preventing occlusion of stented vessels and conduits after implantation of stents
10/31/2002	WO2002085248A2 Prostanoids augment ocular drug penetration
10/31/2002	WO2002085180A2 Vasectomy procedure and related kit
10/31/2002	WO2002085124A1 Use of ppar-alpha-gamma ligands or agonists to prevent the rupture of atherosclerotic plaques
10/31/2002	WO2002085123A1 Ppar-alpha-gamma ligands or agonists for the treatment of inflammation
10/31/2002	WO2002085119A1 Intraoral delivery of nicotine for smoking cessation
10/31/2002	WO2002085117A1 Methods and compositions for preventing and treating septic shock and endotoxemia
10/31/2002	WO2002085113A1 Controlled release particles
10/31/2002	WO2002085093A2 Replikin peptides and uses thereof
10/31/2002	WO2002076935A8 Novel a-lipoic acid derivative and use thereof
10/31/2002	WO2002069895A3 Heterocyclic analgesic compounds and methods of use thereof
10/31/2002	WO2002068390A8 Diamides which inhibit tryptase and factor xa activity
10/31/2002	WO2002068381A3 Aryl-n-cyanoguanidines and methods related thereto
10/31/2002	WO2002067879A3 Material composition and oral galenic form against hair loss and brittle nails
10/31/2002	WO2002067853A3 A combination and method of treatment of hiv and viral diseases, vascular disease and cancer utilizing a cox-2 inhibitor and cystine
10/31/2002	WO2002067654A3 6-substituted pyrazolo[3,4-d]pyrimidin-4-ones useful as cyclin dependent kinase inhibitors
10/31/2002	WO2002066681A9 Reagents and methods for identifying and modulating expression of genes regulated by cdk inhibitors
10/31/2002	WO2002066021A3 Protein kinase d inhibitors and protein kinase 2 inhibitors as agents for inhibiting tumour cells and for stimulating angiogenesis
10/31/2002	WO2002064574A3 Pyridoarylphenyl oxazolidinone antibacterials, and related compositions and methods
10/31/2002	WO2002064022A3 Therapy for cerebral vasospasm
10/31/2002	WO2002062963A3 Methods and compounds for treating neurologic or neuropsychiatric disorders and identifying compounds to treat the same
10/31/2002	WO2002059375A9 Determination of ugt2b7 gene polymorphisms for predicting ugt2b7 substrate toxicity and for optimising drug dosage
10/31/2002	WO2002056892A3 Methods of treating neurological disorders
10/31/2002	WO2002053564A3 Quinuclidine derivatives and their use as m3 antagonists
10/31/2002	WO2002053185A3 Anti-inflammatory use of polycationic compounds
10/31/2002	WO2002053122A3 Skin care product containing retinoids and phytoestrogens in a dual compartment package
10/31/2002	WO2002051855A3 Motilide compounds
10/31/2002	WO2002051535A3 Preparation of microparticles having improved flowability
10/31/2002	WO2002051428A8 Sympathetic-activating perfume composition
10/31/2002	WO2002051385A8 Solid dispersions of nitrate active principles
10/31/2002	WO2002051356A3 Inhalable aztreonam for treatment and prevention of pulmonary bacterial infections
10/31/2002	WO2002049650A3 Pharmaceutical formulation containing thienopyrimidines and antithrombotics, calcium antagonists, prostaglandins or prostaglandin derivatives
10/31/2002	WO2002043713A3 Use of weak opioids and mixed opioid agonists/antagonists for treating urinary incontinence
10/31/2002	WO2002042455A3 Modifier of organelle metalbolism
10/31/2002	WO2002042412A3 Protease inhibitors and their pharmaceutical uses
10/31/2002	WO2002042315A3 Macrolide solvates
10/31/2002	WO2002041896A3 Use of thienopyrimidines
10/31/2002	WO2002041841A3 Compositions for adhesion prevention
10/31/2002	WO2002040474A3 Heterocyclylalkyl piperidine derivatives and their use as antimicrobial agents
10/31/2002	WO2002040029A3 Corticosteroids adducts with natural polysaccharide polymers
10/31/2002	WO2002039977A3 A method for restoring a foot fat-pad
10/31/2002	WO2002036105A3 Use of cortisol-sequestering agents for the treatment of hypercortisolaemia related disorders
10/31/2002	WO2002030415A9 Pravastatin sodium substantially free of pravastatin lactone and epi-pravastatin, and compositions containing same
10/31/2002	WO2002028874A3 Tumor proliferation inhibitors
10/31/2002	WO2002026217A3 Composition for the transdermal delivery of fentanyl
10/31/2002	WO2002022611A3 Caspase inhibitors and uses thereof
10/31/2002	WO2002015842A3 Process for preparation of anhydrous azithromycin
10/31/2002	WO2002013806A3 Compositions containing hypotriglyceridemically active stilbenoids
10/31/2002	WO2002012502A3 Anti-tnf antibodies, compositions, methods and uses
10/31/2002	WO2002008434A3 Bicistronic influenza comprising two genes in tandem
10/31/2002	WO2002005800A3 Compositions for sustained release of analgesic agents, and methods of making and using the same
10/31/2002	WO2002000262A3 Modulation of chromosome function by chromatin remodeling agents
10/31/2002	WO2002000250A3 Hiv-1 vaccines and screening methods therefor
10/31/2002	WO2001098343A3 Conserved diaphanous-related formin autoregulatory domain (dad)
10/31/2002	WO2001091535B1 A combination kit used in the treatment of malaria containing chloroquine and 3-(1-(((4-((6-methoxy-8-quinolinyl)amino)pentyl)amino)-ethylidene)-dihydro-2(3h)furanone enthält
10/31/2002	WO2001087348A3 Multifunctional nanodevice platform
10/31/2002	WO2001070675A3 Inhibitors of histone deacetylase
10/31/2002	WO2001067896A3 Method of producing oily suspensions of water-soluble vitamins
10/31/2002	WO2001059152A3 Polymorphisms in the human cyp2b6 gene and their use in diagnostic and therapeutic applications
10/31/2002	WO2001058855A9 Use of androgen receptor suppressors
10/31/2002	WO2001056563A9 Adamantyl derivatives as anti-cancer agents
10/31/2002	WO2001051633A9 Compositions and methods for the therapy and diagnosis of prostate cancer
10/31/2002	WO2001044243A3 Novel heteroaryl-diazabicycloalkanes
10/31/2002	WO2000062766A3 Uses of ppar-gamma agonists in neutrophil-induced diseases
10/31/2002	US20020162130 Transgenic mouse expressing the human cyclooxygenase-2 gene and neuronal cell cultures derived therefrom
10/31/2002	US20020161399 Compositions, systems, and methods for creating in situ, chemically cross-linked, mechanical barriers
10/31/2002	US20020161262 Use treating various medical conditions, including pain
10/31/2002	US20020161237 (Z)-2-((2-bromo-4-(((3-hydroxybenzyl)amino)carbonyl)benzoyl) -amino)pent-2-enoic acid, for example; useful for treating psoriasis
10/31/2002	US20020161234 Forming a diastereoselective epoxide from a chiral alpha-amino aldehyde
10/31/2002	US20020161231 Intermediate for preparing camptothecin derivatives
10/31/2002	US20020161228 Piperidine compounds
10/31/2002	US20020161226 Quinazolines for treating brain tumor
10/31/2002	US20020161222 Hydrogenation of 5,5-dioxo-2,3-dihydro-1H-pyrrolo-(2,1-c)(1,2,4)benzothiadiazine with a complex of ruthenium dichloride with 2,2'-bis(diphenylphosphine)-1,1'-binaphthyl and 1,2-diphenylethylenediamine as catalyst
10/31/2002	US20020161220 Tetraphosphonate bicyclic trisanhydrides
10/31/2002	US20020161212 BPC-1: a secreted brain-specific protein expressed and secreted by prostate and bladder cancer cells
10/31/2002	US20020161206 For inhibiting tumor cell growth
10/31/2002	US20020161169 Hydrogel-forming system with hydrophobic and hydrophilic components
10/31/2002	US20020161055 Enantiomers of O-desmethyl venlafaxine
10/31/2002	US20020161054 And treatment of Chronic Obstructive Pulmonary Disease and allergic rhinitis
10/31/2002	US20020161049 Use of creatine or creatine analogs for the treatment of diseases of the nervous sysyem
10/31/2002	US20020161048 Glycine substitutes and precursors for treating a psychosis
10/31/2002	US20020161047 Method for preventing and treating visceral pain and gastrointestinal disorders
10/31/2002	US20020161046 Method for treating an inflammation or lesion caused by a virus
10/31/2002	US20020161044 Method for enhanced delivery of oxybutynin and compositions thereof
10/31/2002	US20020161042 Nitric oxide donor composition and method for treatment of anal disorders
10/31/2002	US20020161040 N-ethyloxycarbonyl-4-aminophenol for example, in depigmentation of skin, hair
10/31/2002	US20020161039 Crystalline choline ascorbate
10/31/2002	US20020161038 Inosine 5'-monophosphate dehydrogenase (IMPDH); prodrug having functional group -CO-N(-R)-COO-, a carrier, and an immunosuppressant, anticancer agent, antiviral agent, or anti-vascular hyperproliferation agent
10/31/2002	US20020161036 Chalcone coumarins
10/31/2002	US20020161035 Medicaments for chemotherapeutic treatment of disease

1 ... 5663 5664 5665 5666 5667 5668 5669 5670 5671 5672 5673 5674 5675 5676 5677 5678 5679 5680 5681 5682 5683 ... 7860